Martin Rohrbach

Martin Rohrbach

Partner, Life Sciences

Genomics – a blueprint for successful outcomes?

This month marks the 16th anniversary of the first full publication of the human genome. Far from being old news, the potential of genomics continues to grow. In what’s already a period of transformation for Life Sciences companies, how can they drive value from genomics, and what are the pitfalls to be avoided?
4 1

Refining relabeling of pharmaceuticals

Patient safety is at the heart of drug development and licensing processes. But the duty of care does not stop at launch. Manufacturers must satisfy strict regulatory demands throughout a product’s lifecycle, including re-labeling.
1

Swiss Life Sciences – ready for R&D 2030?

Digitalization and societal shifts are pushing Life Sciences to the brink of transformation. Over the next decade, successful players will need to redefine their R&D activities in order to rein in expenses, respond to shorter product lifecycles and seize opportunities of personalized medicine.
3

Das neue Heilmittelgesetz: Fluch oder Segen?

Das neue Heilmittelgesetz wurde zwar bereits vor 2 Jahren verabschiedet, in Kraft tritt es jedoch vermutlich erst am 1. Januar 2019, nach Abschluss des umfangreichen Vernehmlassungsverfahrens. Ziel und Zweck des Gesetzes ist die Regelung der Zulassung und des Vertriebs von Arzneien.
2

EU Medical Device Regulation: What’s the impact?

Following various incidents in recent years, the control mechanisms for medical devices are being tightened throughout Europe with the new EU Medical Device Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR). What is the impact of these EU regulations for Switzerland and how do you ensure compliance on your end by the time the transition period ends?
4

Digitalization reshuffles the deck in life sciences industry

Life science companies will need an integrated digital data strategy with internal and external processes to stay successful and to make use of the available data. At the center of the new life sciency ecosystem is the patient centric view.
2